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Abstract
Background: Metastases to the central nervous system from different primary cancers are an
oncologic challenge as the overall prognosis for these patients is generally poor. The incidence of
brain metastases varies with type of primary cancer and is probably increasing due to improved
therapies of extracranial metastases prolonging patient's overall survival and thereby time for brain
metastases to develop. In addition, the greater access to improved neuroimaging techniques can
provide earlier diagnosis. The aim of this study was to investigate the feasibility of using proton
magnetic resonance spectroscopy (MRS) and multivariate analyses to characterize brain metastases
originating from different primary cancers, to assess changes in spectra during radiation treatment
and to correlate the spectra to clinical outcome after treatment.
Methods: Patients (n = 26) with brain metastases were examined using single voxel MRS at a 3T
clinical MR system. Five patients were excluded due to poor spectral quality. The spectra were
obtained before start (n = 21 patients), immediately after (n = 6 patients) and two months after
end of treatment (n = 4 patients). Principal component analysis (PCA) and partial least square
regression analysis (PLS) were applied in order to identify clustering of spectra due to origin of
metastases and to relate clinical outcome (survival) of the patients to spectral data from the first
MR examination.
Results: The PCA results indicated that brain metastases from primary lung and breast cancer
were separated into two clusters, while the metastases from malignant melanomas showed no
uniformity. The PLS analysis showed a significant correlation between MR spectral data and survival
five months after MRS before start of treatment.
Conclusion: MRS determined metabolic profiles analysed by PCA and PLS might give valuable
clinical information when planning and evaluating the treatment of brain metastases, and also when
deciding to terminate further therapies.
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Background
Brain metastases are a common oncologic challenge as
approximately 15–20 % of all cancer patients develop
central nervous system metastases. They are the dominat-
ing type of brain tumor and are most frequently caused by
haematogenous spread from a primary cancer in lung,
breast, skin or colon [1]. Survival varies with type and
grade of primary cancer, age at diagnosis as well as extent
of proliferation of the primary cancer [2]. The overall
prognosis of survival for these patients is generally poor
and the management of the disease is a significant chal-
lenge.
A major goal in oncology treatment is to give each patient
an individualized therapeutic regime. In addition to diag-
nosis, the patient's pre-treatment performance status
described by Karnofsky performance score (KPS) and the
recursive partitioning analysis (RPA) is evaluated [3]. The
standard treatment is whole-brain-radiation-therapy
(WBRT) alone or after surgery which may prolong life
from one to nine months [4]. Radiation therapy is the
most common treatment strategy since more than 70 % of
the patients have multiple metastases at the time of diag-
nosis [5]. Chemotherapy may also be used in selected
patients. To decide between different treatment options
various prognostic factors such as age, performance status,
numbers of brain metastases and type of primary cancer
and extent of extracranial metastases activity are evalu-
ated. Some patients get their brain metastases detected
before the primary cancer and a non-invasive identifica-
tion of type of metastases would be of importance for fur-
ther treatment [6]. In order to optimize and avoid
ineffective treatment there are also a need for early evalu-
ation of response. The diagnosis and planning of brain
tumor treatment have become more advanced due to
improved diagnostic neuroimaging tools. One of these is
in vivo magnetic resonance spectroscopy (MRS) which
provides additional information for classifying most
brain tumor types and grades [7-9].
Proton (1H) in vivo MRS can be used to quantify metabo-
lites and monitor response to therapy in brain tumors,
thereby allowing non-invasive monitoring of tumor bio-
chemistry [7]. Previous studies have used 1.5T systems for
classification and characterisations of brain tumors.
Recent clinical instrument operating at 3T has improved
spectral quality related to resolution and signal-to-noise-
ratio [10-12]. The main metabolites in proton spectra of
normal brain tissue are N-acetyl aspartate (NAA), creatine
(Cr) and choline-containing compounds (tCho) at 2.0,
3.0 and 3.2 ppm, respectively. In brain malignancies lipid
signals at 1.3 (methylene) and 0.9 ppm (methyl) appear
when short echo times are used [8,13]. Previous studies
have addressed metabolic changes in primary brain
tumors occurring after radiation therapy [14-16]. The
reports from different groups are not conclusive but
reduction in tCho appears to be a reliable marker for treat-
ment response. Among the parameters being predictive
for poorer outcome in certain patient sub-groups were
higher tCho/Cr and tCho/NAA ratios and higher lipid sig-
nals and lower Cr/NAA ratio [17]. Less is known about
brain metastases and the objectives of this study were to
characterize brain metastases originating from different
primary cancers, to assess changes in spectra during radia-
tion treatment and to correlate the spectra to clinical out-
come for the patients after treatment. Our hypothesis is
that in vivo MRS from different brain metastases analysed
by multivariate analyses distinguish metastases originat-
ing from different primary tumors, and also that MR spec-
tra can indicate clinical outcome for these patients.
Methods
Patients
A total of 26 consecutive patients (18 women and 8 men)
with brain metastases from primary cancers such as breast
(n = 9), lung (n = 9), malignant melanoma (n = 4), colon
(n = 3) and kidney (n = 1) were enrolled in this study. All
patients gave a written informed consent and the study
was approved by the local ethics board; Central Norway
medical reach ethics committee. After contrast enhanced
MRI, metastases larger than 10 mm in diameter were cho-
sen for MRS. The quality evaluation of each MR spectrum,
led to the exclusion of five of the 26 enrolled patients (one
from each primary cancer group). A description of the 21
remaining patients is given in Table 1. Six patients came
to a second examination immediately after completed
radiation treatment and four patients to a third MRI/MRS
examination after additional two months. The same size
of volume of interest (VOI) was used in each of the
repeated examinations. The patients' performance status
(KPS and RPA) was determined before start of treatment.
In vivo MR spectroscopy
MR imaging and spectroscopy examinations were per-
formed using a 3T clinical MR system (Philips Intera, Best,
The Netherlands) equipped with a transmit-receive head
coil. The MRI protocol consisted of conventional T1 – and
T2 – weighted images before and after an intravenous
injection of 0.2 ml Gadodiamide/kg body weight (Omnis-
can™, GE Healthcare). Single voxel 1H MRS was per-
formed after contrast injection on a VOI localized within
the metastases using the point resolved spectroscopy
(PRESS) pulse sequence, repetition time (TR) of 2000 ms
and echo time (TE) of 32/33 ms. When only one metasta-
sis (> 10 mm) was detected, a second MRS acquisition was
performed of the same volume using TE = 144 ms (18
patients). If two or more large metastases were identified
by the MRI, a second spectrum was obtained using the
short TE in one of the other tumors (7 patients). The VOI
was 15 × 15 × 15 or 10 × 10 × 10 mm3, depending on theBMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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size of the actual metastasis, and all localizations were ver-
ified by an experienced neuroradiologist. Bandwidth,
number of points and sampling interval were 2000 Hz/
1024/0.5 ms. Each spectrum was obtained as an average
of 192 measurements, giving an acquisition time of 7
minutes. Shimming (automatic) prolonged the acquisi-
tion time with about three minutes. A routine water
unsuppressed spectrum (16 measurements) obtained at
each examination was used to evaluate the spectrum qual-
ity. A total of 33 spectra with short and 18 spectra with
long TE were obtained from brain metastases during the
MRS examinations. The spectroscopic data were post-
processed using jMRUI [18]. The FIDs were zero-filled (2
K) and a Lorentzian filter (2 Hz) was applied before Fast
Fourier Transformation (FFT). The residual peak of the
water signal was suppressed using Hankel Lanczos Singu-
lar Values Decomposition Filter (HLSVD)[18].
Data analyses
The spectral quality was evaluated by applying the algo-
rithm AMARES to estimate the linewidth (full-width-half-
maximum, FWHM) of the water peak signal in the corre-
sponding water unsuppressed spectra. A mean FWHM ±
SD of water peaks in all spectra was calculated (9.2 ± 2.1
Hz). The mean value with the corresponding positive 99%
CI (2.1 Hz) was chosen as quality criteria. All spectra with
a higher FWHM than 11.3 Hz were excluded from further
data analyses. Spectral data were transferred to the soft-
ware program Unscrambler (CAMO) as ASCII-files, Base-
line offset was adjusted and the lipid signal at 1.3 ppm
was used as a chemical shift reference. The spectra were
mean normalised and examined using principal compo-
nent analysis (PCA) and partial least square regression
analysis (PLS). Only the chemical shift region including
the resonances from lipids to tCho compounds (0.70 –
3.45 ppm/365 spectral points) was investigated. Mean
spectra for each primary cancer group were made to illus-
trate the spectral variations.
PCA was applied in order to identify clustering of spectra
due to origin of metastases based on examination of score
plots and loading profiles. The PCA model compresses or
simplifies high-dimensional data by finding a linear com-
bination of the original variables so the variance is maxi-
mized and new uncorrelated variables, principal
components (PC) are created. To avoid that the model
described too much of the variation in the data i.e. noise,
the number of PCs to retain in the model was kept as low
as possible. PCA was performed with full cross validation
and mean centering.
The PLS was applied in order to relate clinical outcome of
the patients (survival or not at five months after first MR
examination) to the spectral data (obtained at first MR
examination). PLS is the regression extension of the PCA
and the data are reduced into PLS factors which explain
Table 1: Patient characteristic. Treatment and clinical outcome data for all patients with approved MR spectra.
Patient 
no.
Sex, Age Primary 
cancer
Brain 
mets
Mets other 
sites than brain
KPS RPA Survival 
(months)
Treatment Time: diagnosis- 
1.MRS (weeks)
Spectral data TE, 
VOI1,2
1 F, 52 Breast Single Brain only 90 1 13+ S + 3Gyx10 5 32,1441
2 M, 44 Lung Single Brain only* 90 1 10+ S 1 33,1442
3a F, 47 Lung Multiple Brain only 90 1 7+ C 0 32,1441
4a F, 45 Breast Multiple Mediastinum 100 2 15+ S + 3Gyx10 1 33,1442
5a F, 48 Breast Multiple Skeleton* 100 2 5+ 3Gyx10 0 332
6 F, 57 Lung Multiple Intestinal, 
jejunum
100 2 7 3Gyx10 4 32,1441
7 M, 63 Lung Multiple Lung, skeleton 100 2 6 3Gyx10 2 32,1441
8 M, 62 Lung Single Skeleton 90 2 4.5 S + 3Gyx10 4 33,1442
9 M, 70 Mal. mel. Multiple Lung, subcutan* 90 2 2 S + 3Gyx10 3 33 in 2 VOI2
10 F, 36 Breast Multiple Liver, skeleton 80 2 9 4Gyx5 (GK) 1 32,1441
11 F, 47 Breast Multiple Liver 80 2 10 3Gyx10 2 32,1441
12b F, 66 Breast Multiple Brain only 80 2 2 3Gyx10 3 33 in 2 VOI2
13 M, 70 Colon Single Liver, lung 80 2 6 S + 4Gyx5 17 33,1441
14b F, 80 Lung Multiple Brain only 80 2 0.75 4Gyx5 1 33 in 2 VOI2
15a F, 71 Lung Multiple Brain only 80 2 3 3Gyx10 4 33 in 2 VOI2
16 F, 72 Breast Multiple Liver, skeleton 60 3 0.5 4Gyx5 2 33,1442
17 M, 69 Colon Single Liver, lung 60 3 6 S + 3Gyx10 5 32,1441
18a F, 53 Lung Multiple Brain only* 60 3 11+ 4Gyx5 2 33 in 2 VOI2
19 M, 56 Mal. mel. Multiple Epigastrium 60 3 1 No Treatment 2 332 and 321
20 F, 63 Breast Single Lung, skeleton, 
lymph node
50 3 0.5 No treatment 0 33,1442
21 F, 71 Mal. mel. Single Lung, liver 50 3 1.5 3Gyx10 8 32,1441
F = female, M = male, mets = metastases, a: three MRS follow-up examinations, b: two follow-up MRS examinations, *: brain metastases detected 
before primary cancer, KPS = Karnofsky Performance Score, RPA = Recursive Partitioning Analysis classification, TE = echo time, VOI1,2 = volume 
of interest, 1: voxel size: 15 × 15 × 15 mm3, 2: 10 × 10 × 10 mm3. Mal. mel. = malignant melanoma, GK = gamma knife, S = Brain surgery and 
histopathologic verification, C = Chemotherapy.BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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most of the variation in both predictors (MR spectra) and
responses (clinical parameters). The number of PCs to
remain in the model was determined by finding the PC
where the total residual y-variance and root mean square
error of prediction (RMSEP) were minimized. For the PLS
analysis the test set method was used as validation
method. The test samples were selected in advance by
using the Kennard Stones algorithm for splitting data sets
into two subsets [19], resulting in 14 samples for calibra-
tion and 7 samples for testing. The significance of the esti-
mated correlation factors between measured and
predicted y-variables was ascertained by using the Pearson
correlation test (two-tailed).
Results
Of the 33 short echo time spectra obtained from the
enrolled 26 patients, six spectra were excluded due to a
FWHM of the water signal larger than 11.3 Hz, likewise
four of the eighteen spectra obtained at TE 144, leaving 27
spectra with short and 14 with long echo time for further
analyses.
Spectra from two distinct metastases were obtained in six
patients (Table 1). Typical axial T1 weighted contrast
enhanced MR images with corresponding in vivo spectra
of metastases in two breast cancer patients are given in Fig.
1. Mean spectra (short TE) ± 95% CI of the four different
primary cancer groups are shown in Fig. 2. The lipid sig-
nals at 1.3 and 0.9 ppm were the dominating peaks in the
majority of the spectra in all groups. Cr, tCho and a broad
peak around 2.0 – 2.2 ppm were also detected in 17, 20
and 22 of the 27 spectra, respectively.
Brain metastases in vivo spectra Figure 1
Brain metastases in vivo spectra. Axial T1 weighted contrast enhanced MR images of two patients with brain metastases 
from breast cancer (patient 1 and 12) with corresponding spectra. A: short echo time spectra of two metastases (a and b). B: 
Short and long echo time spectra in the same VOI. The lipid peak at 1.3 ppm in the short echo time spectrum is cut due to the 
chosen scaling.BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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The score plot from PCA of the 27 short echo time spectra
obtained before start of treatment is presented in Fig. 3a.
This plot indicates that brain metastases from primary
lung and breast cancer tend to cluster, while the metas-
tases from malignant melanomas show no uniformity.
The two spectra of metastases from colon cancer are found
in the lower right quadrant of the score plot. The separa-
tion of breast and lung metastases is based on PC1 and
PC2, which account for more than 83 % of the total vari-
ation of the spectra. Samples with high score for PC1 are
characterized by high lipid signal and no other metabo-
lites, as described by the loading profile of PC1 (Fig. 3b).
Figure 4 gives a score plot of PC1 versus PC2 from the PLS
relating spectra of untreated metastases to survival five
months after treatment. The first two PCs explained
totally 85 % of the x-variables (the spectral data) and 53
% of the y-variable (survival). The correlation factor
between measured and predicted survival were 0.73 (p <
0.01) for the calibration run and 0.76 (p < 0.05) for the
corresponding validation (seven test samples). The spec-
tra of patients who survived five months after first MRS
(marked as circles) are clustered on the right side of the
score plot, while the spectra of patients who survived less
than five months (cross marks) are clustered in the oppo-
site side.
Follow-up MRS examinations where completed only for
four of the included patients, since some got a complete
surgical resection of the metastasis, a few refused further
examinations and some died shortly after the first or sec-
ond examination (Table 1). Two examples of the follow-
Mean spectra Figure 2
Mean spectra. Short echo time mean spectra ± 95% CI of brain metastases from different primary cancer. A: lung cancer (n 
= 11 spectra), B: breast cancer (n = 9 spectra), C: malignant melanoma (n = 5 spectra), D: colon cancer (n = 2 spectra). The 0.7 
– 3.4 ppm area of the spectra and the detected metabolites (in ppm) are given; tCho (3.2), Cr (3.0): creatine and lipids (1.3, 
0.9): methylene and methyl groups.BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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up spectra are shown in Fig. 5. At the last examination
four of the seven obtained spectra (four patients) showed
decreased levels of the lipid signal (30–80 % peak inten-
sity of mean normalized spectra). Of the ten second exam-
ination spectra six showed minor changes in the
metabolite distribution, while three spectra indicated an
increase in the 1.3 ppm lipid peak relative to the signal of
methyl at 0.9 ppm. The tenth spectra, obtained from the
patient treated with chemotherapy showed an increasing
signal of NAA and Cr peak relative to Cho-containing sig-
nals at 3.2 ppm indicating normal brain tissue enclosed in
the VOI due to the shrinking metastasis during the treat-
ment period.
Discussion
The results presented here demonstrate that the lipid sig-
nals are important in brain metastases characterization.
The clustering of spectra from brain metastases from
breast and lung cancer in the PCA score plot is described
by PC1 showing the lipid signal as the dominating differ-
ence. The lipid signals are also an important factor in the
PLS relating MR spectra to clinical outcome. These signals
change after radiation therapy, which is in accordance to
previous studies [14,16]. Many cellular processes such as
proliferation, inflammation, malignancy, necrosis,
growth arrest and apoptosis, have been linked to altera-
tions in MR visible lipid levels. Intracellular lipid bodies
appear to be the most important contributors [20,21].
However, which biochemical processes that lead to lipid
accumulation of MR visible signals is still enigmatic, and
the source and complete characteristics of the lipids found
mostly in high grade brain tumors are still not elucidated
[21,22].
PCA results Figure 3
PCA results. Part a: Score plot of PC1 versus PC2 of water suppressed in vivo spectra. ● = breast cancer (n = 9), X = lung 
cancer (n = 11), O = malignant melanoma (n = 5), ▼ = colon cancer (n = 2). Part b: The loading profile of PC1 showing differ-
ences in the lipid signals.BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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Small signals of intracellular lipids might be observed in
normal brain tissue in short echo time spectra and these
signals are often increased in malignancies. In accordance
with previous studies of brain tumors [8,14], increased
signals of lipids and also tCho compounds were detected
in the majority of all spectra of brain metastases obtained
with short echo time in this study (Fig. 2). The other main
metabolites in spectra from normal brain tissue, NAA and
Cr were definitely reduced in these spectra. The high
intensity lipid signals and low levels of Cr are typical for
metastases and have been used to differentiate these
lesions from primary brain tumors [22-25]. However, the
spectral differences between metastases and high grade
gliomas are small and these two groups might be hard to
distinguish [23]. Methylene components in fatty acids
give rise to a broad peak around 2.0 – 2.2 ppm [21] and
this might overlap any possible NAA present. At longer
echo time the lipid signals will be reduced due to short
relaxation time [26], and in seven of the fourteen spectra
obtained at TE 144, a small peak of NAA could be
observed. Previous studies have interpreted that signal
from NAA in metastases is due to the presence of viable
neurons within an infiltrative tumour or contamination
from normal brain tissue since NAA is a neuron specific
metabolite [24,27].
The use of multivariate analyses can reveal features in the
spectra which may not be detectable with traditional sta-
tistical analyses of peak integral ratios [28,29]. The mean
spectra from the different primary cancer groups showed
minor differences in distribution of the metabolites. Still,
the spectra from metastases in breast and lung cancer
patients tend to cluster into different parts of the PCA
score plot, the separation being mainly due to differences
PLS score plot Figure 4
PLS score plot. Score plot of spectra from patients who lived longer than five months (❍), and they who passed away before 
five months after the first MR spectra examination (†). The numbers refers to patient numbers in Table 1. Some patients were 
examined for two metastases (a and b).BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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in the lipid signals as described by PC1 (Fig. 3b). The dis-
persion of the malignant melanoma spectra in the PCA
score plot (Fig. 3a) reflects the large confidence interval
for the corresponding averaged spectra (Fig. 2c).
In this study, PLS was used to relate spectral data to clini-
cal outcome for each patient. A trend of two separate clus-
ters of patients surviving five months versus patients
passing away before five months can be observed in the
score plot (Fig. 4) The loading weights from PLS indicate
that resonances in the ppm regions 0.8 – 0.9, 1.8 – 2.2 and
2.5 – 2.8 ppm representing different lipid signals are most
important for the prediction. By seeing the patients' per-
formance status in conjunction with the respective locali-
zation in the score plot (Fig. 4), patients classified as RPA2
and 3 are dispersed across the plot, while the RPA1 classi-
fied patients are clustered in the intermediate area.
Patients classified as RPA3 might be interpreted to have a
better prognosis if the spectral data appear to be in the sur-
vival area of the score plot. Thus, the use of multivariate
analysis on the spectral data might be of importance to
predict the outcome for patients with brain metastases.
Half of the patients in this study received radiation ther-
apy and the follow-up spectroscopy examinations were
done immediately after completed treatment. However,
only a few of these patients were able to fulfil the study
protocol due to their health condition. The changes in
level of mobile lipids and choline observed in spectra
obtained after completed radiation therapy could reflect
effects of the treatment observed at a metabolic level.
Graves et al. [30] have previously shown changes in the
metabolic profile of recurrent gliomas up to 14 months
after gamma knife surgery. They observed an increase in
the lactate/lipid resonance that developed early after the
treatment but was reduced later in the follow-up of these
glioma patients. Nelson [31] reported that the intensity of
the tCho, Cr, and NAA signal decreased with time after
radiation treatment of gliomas, and the lactate/lipid ratio
increased to a maximum four months after the end of
radiation. This is interpreted to represent a reduction in
tumor and formation of treatment-induced necrosis. Pos-
sibly, the changes observed in the present study of brain
metastases could be caused by the same mechanisms.
Single voxel spectroscopy has been extensively used in
examination of brain tumors [8,22,24,26] and has been
included in routine MRI protocols for tumor diagnostics
at several sites. Differentiation of most tumor types has
been successfully reported and a clinical decision support
system for classification of brain tumors, INTERPRET, has
recently been developed [32]. The short acquisition time
makes it simple to include it in a clinical MRI exam and
the 3T generation of MR instruments will give better spec-
Follow-up spectra Figure 5
Follow-up spectra. Spectra of brain metastases from patients with primary breast (patient 4) and lung cancer (patient 15), 
before (-I), immediately after (-II) and two months after end of radiation treatment (-III). The patients' survival was more than 
16 months and only 3 months, respectively.BMC Cancer 2007, 7:141 http://www.biomedcentral.com/1471-2407/7/141
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tral resolution and signal-to-noise ratio with equal effec-
tive size of VOI [12]. The spatial resolution will, however,
be poor compared to MR Spectroscopic Imaging (MRSI).
Using MRSI, several single voxels over a wider area
become examined at the same time and metabolite distri-
bution in both tumor and surrounding normal tissue are
explored. However, single voxel MRS is less time consum-
ing both during optimization and acquisition than MRSI.
The signal from the whole metastasis was used for study-
ing the metabolic phenotype in these analyses.
The exclusion criterion used in this study was the mean
FWHM value for the corresponding unsuppressed water
signal of the obtained spectra. This threshold value should
not be considered as an exact threshold normative for
other studies due to the small group investigated. How-
ever, the method of excluding spectra that are outside the
99% confidence interval of the data could be a used as a
standardized quality control. The exclusion criterion
excluded five of the enrolled twenty-six patients. Due to
their bad health condition, some of the patients where
uncomfortable during the examination which could cause
motion artefacts, while in three of the patients the metas-
tases were localized near the skull or close to cerebellum.
The use of contrast agent has shown no significant effect
on metabolite signal intensities at 1.5T [33,34]. The effect
of the contrast agent has not been tested in this study.
However, for clinical MRS studies of brain metastases in
vivo the contrast agent will always be present as a part of
the routine MRI protocol.
Spectrum quality also depends on the voxel size. The spec-
tral SNR increases linearly with the voxel size and with the
square root of the number of acquisitions [35]. To obtain
maximum SNR within acceptable examination time, the
number of acquisitions used was chosen as many as pos-
sible, resulting in 192 acquisitions during a seven minutes
examination. In about half of the patient group, the small-
est possible voxel size was used due to the size of the
metastasis. Hence, these cases should give reduced SNR
compared to the other cases where the cubic sides where
15 mm. Among the excluded spectra two out of five where
obtained using the largest volume size.
A clear limitation of the present study is the small and het-
erogeneous group of patients and increased number of
patients to further validate the clinical value of the PLS
model is necessary. A possible bias could be the skewed
distribution of the subgroups of brain metastases. There
were twice as many patients with brain metastases from
breast and lung cancer as the other groups. This reflects
however the incidence of brain metastases from the differ-
ent type of primary cancer [1].
Conclusion
The in vivo metabolic MR profiles of brain metastases
demonstrated variations due to origin of primary cancer
and as an effect of radiation treatment. A correlation
between MR profiles and survival at five months was also
found. Thus, MR determined metabolic profiles might
contain valuable clinical information for planning and
evaluation of brain metastasis treatment.
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